Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline from the american college of physicians

Amir Qaseem, Linda Humphrey, Donna E. Sweet, Melissa Starkey, Paul Shekelle

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medications. Methods: This guideline is based on a systematic evidence review evaluating literature published on this topic from 1966 through April 2010 that was identified by using MEDLINE (updated through December 2010), EMBASE, and the Cochrane Central Register of Controlled Trials. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular morbidity, neuropathy, nephropathy, and retinopathy. This guideline grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system. Recommendation 1: ACP recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately improve hyperglycemia (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence). Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; highquality evidence).

Original languageEnglish (US)
Pages (from-to)218-231
Number of pages14
JournalAnnals of Internal Medicine
Volume156
Issue number3
StatePublished - Feb 7 2012
Externally publishedYes

Fingerprint

Practice Guidelines
Type 2 Diabetes Mellitus
Metformin
Physicians
Hyperglycemia
Guidelines
Life Style
Reducing Diet
Morbidity
Therapeutics
Mortality
MEDLINE
Publications
Language
Exercise
Safety

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Oral pharmacologic treatment of type 2 diabetes mellitus : A clinical practice guideline from the american college of physicians. / Qaseem, Amir; Humphrey, Linda; Sweet, Donna E.; Starkey, Melissa; Shekelle, Paul.

In: Annals of Internal Medicine, Vol. 156, No. 3, 07.02.2012, p. 218-231.

Research output: Contribution to journalArticle

@article{2647dbd350d844e4b263da8bcdb2511c,
title = "Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline from the american college of physicians",
abstract = "Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medications. Methods: This guideline is based on a systematic evidence review evaluating literature published on this topic from 1966 through April 2010 that was identified by using MEDLINE (updated through December 2010), EMBASE, and the Cochrane Central Register of Controlled Trials. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular morbidity, neuropathy, nephropathy, and retinopathy. This guideline grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system. Recommendation 1: ACP recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately improve hyperglycemia (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence). Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; highquality evidence).",
author = "Amir Qaseem and Linda Humphrey and Sweet, {Donna E.} and Melissa Starkey and Paul Shekelle",
year = "2012",
month = "2",
day = "7",
language = "English (US)",
volume = "156",
pages = "218--231",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Oral pharmacologic treatment of type 2 diabetes mellitus

T2 - A clinical practice guideline from the american college of physicians

AU - Qaseem, Amir

AU - Humphrey, Linda

AU - Sweet, Donna E.

AU - Starkey, Melissa

AU - Shekelle, Paul

PY - 2012/2/7

Y1 - 2012/2/7

N2 - Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medications. Methods: This guideline is based on a systematic evidence review evaluating literature published on this topic from 1966 through April 2010 that was identified by using MEDLINE (updated through December 2010), EMBASE, and the Cochrane Central Register of Controlled Trials. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular morbidity, neuropathy, nephropathy, and retinopathy. This guideline grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system. Recommendation 1: ACP recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately improve hyperglycemia (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence). Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; highquality evidence).

AB - Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medications. Methods: This guideline is based on a systematic evidence review evaluating literature published on this topic from 1966 through April 2010 that was identified by using MEDLINE (updated through December 2010), EMBASE, and the Cochrane Central Register of Controlled Trials. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular morbidity, neuropathy, nephropathy, and retinopathy. This guideline grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system. Recommendation 1: ACP recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately improve hyperglycemia (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence). Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; highquality evidence).

UR - http://www.scopus.com/inward/record.url?scp=84856740961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856740961&partnerID=8YFLogxK

M3 - Article

C2 - 22312141

AN - SCOPUS:84856740961

VL - 156

SP - 218

EP - 231

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -